Oktay BULUR, Muhammed Saçıkara, Mehmet Polat, Yaşar Nazlıgül

HELİKOBAKTER PİLORİ ERADİKASYONUNUN SERUM PARAOKSONAZ ENZİM AKTİVİTESİNE ETKİSİ

Amaç: Helikobacter pilori (H. pylori) enfeksiyonu gastrointestinal ve ekstraintestinal hastalıklarla ilişkilidir. H. pylori bu hastalıklara spesifik virülans faktörleri yoluyla veya inflamasyon ve oksidasyonu arttırarak neden olur. High-Density Lipoprotein (HDL) kolesterol ile ilişkili paraoksonaz-1 (PON-1) enzimi, HDL kolesterolün antioksidan ve antiaterojenik etkilerinden sorumludur. PON1 seviyeleri bu nedenle kardiyovasküler hastalıklarla ilişkilidir. Bu çalışmada H. pylori eradikasyonu ile eradike olan ve olmayan hastaların serum paraoksonaz aktivitesi açısından kıyaslanması amaçlanmıştır. Gereç ve Yöntem: Çalışma H. pylori eradikasyon tedavisi almış ve eradikasyon tedavisi kontrol edilmiş 126 yetişkin hastada prospektif olarak yapıldı. Eradikasyon tedavisi sonrasında H. pylori 38 hastada (17 erkek, 21 kadın) pozitif, 88 hastada (43 erkek, 45 kadın) negatifti. Bu iki grup serum PON-1 seviyeleri açısından karşılaştırıldı. Bulgular: H. pylori eradikasyon tedavisi sonrası PON-1 enzim seviyeleri; H. pylori negatif grupta 165,69 U/L ve H. pylori pozitif grupta 131,68 U/L olarak bulundu. Tedaviden sonra gruplar arasında PON-1 enzim seviyeleri açısından istatistiksel olarak anlamlı fark saptandı (p=0,02). Sonuç: H. pylori eradikasyon tedavisi sonrası PON-1 enzim seviyelerinde artış, low density lipoprotein (LDL) oksidasyonunda azalmaya ve buna sekonder antiaterosklerotik etkiye neden olmaktadır.

THE EFFECT OF HELICOBACTER PYLORI ERADICATION ON PARAOXONASE ENZYME ACTIVITY

AIM: Helicobacter pylori (H. pylori) infection is associated withgastrointestinal and extra-gastrointestinal diseases either directly viaits special virulence factors or indirectly by increasing inflammationand oxidation. Paraoxonase-1 (PON-1) enzyme that is related toHigh-Density Lipoprotein (HDL) cholesterol is responsible for theantioxidant and antiatherogenic effects of HDL cholesterol. PON–1level is related to the risk of cardiovascular disease. We aimed toinvestigate the relation between H. pylori infection and PON-1activity.MaterIal AND Method: The study was performedprospectively in 126 H.pylori positive adult patients. Afterperforming eradication therapy and checking the treatment success,38 H. pylori-positive (17 male, 21 female) and 88 H. pylori-negative(43 male, 45 female) patients were included in this study. Thesegroups were compared in terms of serum PON-1 levels.Results: PON–1 enzyme levels were found to be 165.69 U/L inH. pylori -negative and 131.68 U/L in H. pylori -positive groupsafter H. pylori eradication therapy. After treatment, the difference inPON–1 enzyme levels was statistically significant (p=0.02).ConclusIon: Increased PON–1 enzyme levels after H. pylorieradication therapy might play a role in the antiatherosclerotic effectby reducing LDL oxidation.

PDF

___

1.)Xia HX, Keane CT, Chen J et.al. Transportation of Helicobacter pylori cultures by optimal systems. Journal of Clinical Microbiology. 1994;32(12):3075-7.
2.)Kato M, Toda A, Yamamoto-Honda R, Arase Y, Sone H Association between Helicobacter pylori infection, eradication and diabetes mellitus. J Diabetes Investig. 2019; 10(5):1341-1346.
3.)Howden CW. Clinical expressions of Helicobacter pylori infection. The American journal of Medicine. 1996;100(5A):27S-32S.
4.)Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19(3):449-90
5.)Sun J, Rangan P, Bhat SS, Liu L.A Meta-Analysis of the Association between Helicobacter pylori Infection and Risk of Coronary Heart Disease from Published Prospective Studies. Helicobacter. 2016;21(1):11-23
6.)Malfertheiner P, Megraud F, O'Morain CA et.al. European H, Microbiota Study G, Consensus p. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66(1):6-30.
7.)Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 1998;139(2):307-15.
8.)Mackness MI, Harty D, Bhatnagar D et.al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86(2-3):193-9.
9.)Gateva A, Assyov Y, Tsakova A, Kamenov Z. Serum Paraoxonase-1 Levels are Significantly Decreased in the Presence of Insulin Resistance. Experimental and Clinical Endocrinology & Diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2016;124(7):444-7.
10.)Sutherland WH, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arteriosclerosis, thrombosis, and vascular biology. 1999;19(5):1340-7.
11.)Chandra M, Chandra N, Agrawal R, Kumar A, Ghatak A, Pandey VC. The free radical system in ischemic heart disease. International Journal of Cardiology 1994;43(2):121-5.
12.)Ding J, Chen Q, Zhuang X, Feng Z, Xu L, Chen F. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease. Medical Science monitor : International Medical Journal of Experimental and Clinical Research 2014;20:2421-9.
13.)Erenler AK, Kocabas R, Dogan T, Erdemli HK, Yetim M. Paraoxanase as an indicator of myocardial ischemia and its utility in determining extension of ischemia. The American Journal of Emergency Medicine. 2016;34(1):45-8. doi: 10.1016/j.ajem.2015.09.008. PubMed PMID: 26475358.
14.)Singh K, Singh R, Chandra S, Tyagi S. Paraoxonase-1 is a better indicator than HDL of Atherosclerosis - A pilot study in North Indian population. Diabetes & Metabolic Syndrome. 2018;12(3):275-8.
15.)Fulop P, Harangi M, Seres I, Paragh G. Paraoxonase-1 and adipokines: Potential links between obesity and atherosclerosis. Chemico-Biological Interactions 2016;259(Pt B):388-93
16.)Chistiakov DA, Melnichenko AA, Orekhov AN, Bobryshev YV. Paraoxonase and atherosclerosis-related cardiovascular diseases. Biochimie. 2017;132:19-27.
17.)Jelena Kotur-Stevuljevic JV, Aleksandra Stefanovic , Aleksandra Zeljkovic et.al Paraoxonase-1 and atherosclerosis-related diseases. Biofactors 2020;46:193-205.
18.)Lioudaki S, Verikokos C, Kouraklis G, et.al. Paraoxonase-1: Characteristics and role in atherosclerosis and carotid artery disease. Current Vascular Pharmacology 2019;17(2):141-6.
19.)Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350(9075):430-6.
20.)Mendall MA, Goggin PM, Molineaux N et. al.Relation of Helicobacter pylori infection and coronary heart disease. British Heart Journal 1994;71(5):437-9.
21.)Kowalski M, Pawlik M, Konturek JW, Konturek SJ. Helicobacter pylori infection in coronary artery disease. Journal of Physiology and Pharmacology: an official journal of the Polish Physiological Society. 2006;57 Suppl 3:101-11.
22.)Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 1992;268(1):68-72.
23.)Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2(8618):983-6.
24.)Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. The Journal of Iinfectious Diseases. 1997;176(1):292-5.
25.)Gunn M, Stephens JC, Thompson JR, Rathbone BJ, Samani NJ. Significant association of cagA positive Helicobacter pylori strains with risk of premature myocardial infarction. Heart 2000;84(3):267-71.
26.)Obermayer G, Afonyushkin T, Binder CJ. Oxidized lowdensity lipoprotein in inflammation-driven thrombosis. Journal of thrombosis and haemostasis: JTH. 2018;16(3):418-28.
27.)Aviram M, Hardak E, Vaya J et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101(21):2510-7.
28.)Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in atherosclerosis. Current Atherosclerosis Reports 2017;19(11):42.
29.)Serdar Z, Aslan K, Dirican M, Sarandol E, Yesilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem. 2006;39(8):794-803.
30.)Azarsiz E KM, Payzin S, Sözmen EY. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 2003;91:43-51.
31.)Kunutsor SK, Bakker SJ, James RW, Dullaart RP. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis. 2016;245:143-54.